{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:46:11Z","timestamp":1789962371211,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970446"],"award-info":[{"award-number":["81970446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"DOI":"10.1007\/s10753-025-02309-1","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T18:01:27Z","timestamp":1747245687000},"page":"4031-4045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitor Ameliorate Angiotensin II-Induced Hypertension and Vascular Injury by Upregulating FGF21"],"prefix":"10.1007","volume":"48","author":[{"given":"Manyu","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangcheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2309_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/HYPERTENSIONAHA.117.07802","volume":"70","author":"T J Guzik","year":"2017","unstructured":"Guzik, T. J., and R. M. Touyz. 2017. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension 70:660\u2013667.","journal-title":"Hypertension"},{"issue":"17","key":"2309_CR2","doi-asserted-by":"publisher","first-page":"e170845","DOI":"10.1172\/jci.insight.170845","volume":"8","author":"M Arevalo Martinez","year":"2023","unstructured":"Arevalo Martinez, M., O. Ritsvall, J. A. Bastrup, S. Celik, G. Jakobsson, F. Daoud, C. Winqvist, A. Aspberg, C. Rippe, L. Maegdefessel, A. Schiopu, T. A. Jepps, J. Holmberg, K. Sward, and S. Albinsson. 2023. Vascular smooth muscle-specific YAP\/TAZ deletion triggers aneurysm development in mouse aorta. JCI Insight 8 (17): e170845.","journal-title":"JCI Insight"},{"key":"2309_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41392-023-01577-3","volume":"8","author":"Y Qiu","year":"2023","unstructured":"Qiu, Y., S. Xu, X. Chen, X. Wu, Z. Zhou, J. Zhang, Q. Tu, B. Dong, Z. Liu, J. He, X. Zhang, S. Liu, C. Su, H. Huang, W. Xia, and J. Tao. 2023. NAD(+) exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. Signal Transduction and Targeted Therapy 8:353.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2309_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","volume":"132","author":"M Burnier","year":"2023","unstructured":"Burnier, M., and A. Damianaki. 2023. Hypertension as cardiovascular risk factor in chronic kidney disease. Circulation Research 132:1050\u20131063.","journal-title":"Circulation Research"},{"key":"2309_CR5","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G., R. Kreutz, M. Brunstrom, M. Burnier, G. Grassi, A. Januszewicz, M.L. Muiesan, K. Tsioufis, E. Agabiti-Rosei, E. A. E. Algharably, M. Azizi, A. Benetos, C. Borghi, J. B. Hitij, R. Cifkova, A. Coca, V. Cornelissen, J. K. Cruickshank, P. G. Cunha, A. H. J. Danser, R. M. Pinho, C. Delles, A. F. Dominiczak, M. Dorobantu, M. Doumas, M. S. Fernandez-Alfonso, J. M. Halimi, Z. Jarai, B. Jelakovic, J. Jordan, T. Kuznetsova, S. Laurent, D. Lovic, E. Lurbe, F. Mahfoud, A. Manolis, M. Miglinas, K. Narkiewicz, T. Niiranen, P. Palatini, G. Parati, A. Pathak, A. Persu, J. Polonia, J. Redon, P. Sarafidis, R. Schmieder, B. Spronck, S. Stabouli, G. Stergiou, S. Taddei, C. Thomopoulos, M. Tomaszewski, P. Van de Borne, C. Wanner, T. Weber, B. Williams, Z. Y. Zhang, and S. E. Kjeldsen. 2023. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension 41:1874\u20132071.","journal-title":"Journal of Hypertension"},{"key":"2309_CR6","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"J W McEvoy","year":"2024","unstructured":"McEvoy, J. W., C. P. McCarthy, R. M. Bruno, S. Brouwers, M. D. Canavan, C. Ceconi, R. M. Christodorescu, S. S. Daskalopoulou, C. J. Ferro, E. Gerdts, H. Hanssen, J. Harris, L. Lauder, R. J. McManus, G. J. Molloy, K. Rahimi, V. Regitz-Zagrosek, G. P. Rossi, E. C. Sandset, B. Scheenaerts, J. A. Staessen, I. Uchmanowicz, M. Volterrani, R. M. Touyz, Group, E. S. C. S. D. 2024. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal 45:3912\u20134018.","journal-title":"European Heart Journal"},{"issue":"8","key":"2309_CR7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41440-024-01723-6","volume":"47","author":"P Ahwin","year":"2024","unstructured":"Ahwin, P., and D. Martinez. 2024. The relationship between SGLT2 and systemic blood pressure regulation. Hypertension Research 47 (8): 2094\u20132103.","journal-title":"Hypertension Research"},{"key":"2309_CR8","doi-asserted-by":"publisher","first-page":"109825","DOI":"10.1016\/j.cellsig.2020.109825","volume":"77","author":"S Sukhanov","year":"2021","unstructured":"Sukhanov, S., Y. Higashi, T. Yoshida, S. Mummidi, A. R. Aroor, J. Jeffrey Russell, S. B. Bender, V. G. DeMarco, and B. Chandrasekar. 2021. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1beta and IL-18 secretion. Cellular Signalling 77:109825.","journal-title":"Cellular Signalling"},{"key":"2309_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1007\/s12325-019-01043-z","volume":"36","author":"A Nicolucci","year":"2019","unstructured":"Nicolucci, A., R. Candido, D. Cucinotta, G. Graziano, A. Rocca, M. C. Rossi, F. Tuccinardi, and V. Manicardi. 2019. Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: Implications for clinical practice. Advances in Therapy 36:2895\u20132909.","journal-title":"Advances in Therapy"},{"key":"2309_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.pcad.2020.04.003","volume":"63","author":"K Kario","year":"2020","unstructured":"Kario, K., K. C. Ferdinand, and J. H. O\u2019Keefe. 2020. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress in Cardiovascular Diseases 63:249\u2013262.","journal-title":"Progress in Cardiovascular Diseases"},{"key":"2309_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q., S. Zhou, and L. Liu. 2023. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: A new meta-analysis. Diabetology and Metabolic Syndrome 15:118.","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"2309_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/ajh\/hpz157","volume":"33","author":"E A Sanidas","year":"2020","unstructured":"Sanidas, E. A., D. P. Papadopoulos, E. Hatziagelaki, C. Grassos, M. Velliou, and J. Barbetseas. 2020. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension. American Journal of Hypertension 33:207\u2013213.","journal-title":"American Journal of Hypertension"},{"key":"2309_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","volume":"21","author":"A J Scheen","year":"2019","unstructured":"Scheen, A. J. 2019. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Current Cardiology Reports 21:70.","journal-title":"Current Cardiology Reports"},{"key":"2309_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11906-019-0920-4","volume":"21","author":"H Sternlicht","year":"2019","unstructured":"Sternlicht, H., and G. L. Bakris. 2019. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): More than osmotic diuresis. Current Hypertension Reports 21:12.","journal-title":"Current Hypertension Reports"},{"key":"2309_CR15","doi-asserted-by":"publisher","first-page":"102272","DOI":"10.1016\/j.coph.2022.102272","volume":"66","author":"M Chiriaco","year":"2022","unstructured":"Chiriaco, M., D. Trico, and A. Solini. 2022. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. Current Opinion in Pharmacology 66:102272.","journal-title":"Current Opinion in Pharmacology"},{"key":"2309_CR16","doi-asserted-by":"publisher","first-page":"e015323","DOI":"10.1161\/JAHA.119.015323","volume":"9","author":"M Hu","year":"2020","unstructured":"Hu, M., X. Cai, W. Yang, S. Zhang, L. Nie, and L. Ji. 2020. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: A meta-analysis. Journal of the American Heart Association 9:e015323.","journal-title":"Journal of the American Heart Association"},{"key":"2309_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/joim.12580","volume":"281","author":"A Kharitonenkov","year":"2017","unstructured":"Kharitonenkov, A., and R. DiMarchi. 2017. Fibroblast growth factor 21 night watch: Advances and uncertainties in the field. Journal of Internal Medicine 281:233\u2013246.","journal-title":"Journal of Internal Medicine"},{"key":"2309_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","volume":"3","author":"K H Flippo","year":"2021","unstructured":"Flippo, K. H., and M. J. Potthoff. 2021. Metabolic messengers: FGF21. Nature Metabolism 3:309\u2013317.","journal-title":"Nature Metabolism"},{"key":"2309_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng, L., K. S. L. Lam, and A. Xu. 2020. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nature Reviews. Endocrinology 16:654\u2013667.","journal-title":"Nature Reviews. Endocrinology"},{"key":"2309_CR20","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.122.059631","volume":"146","author":"L Jin","year":"2022","unstructured":"Jin, L., L. Geng, L. Ying, L. Shu, K. Ye, R. Yang, Y. Liu, Y. Wang, Y. Cai, X. Jiang, Q. Wang, X. Yan, B. Liao, J. Liu, F. Duan, G. Sweeney, C. W. H. Woo, Y. Wang, Z. Xia, Q. Lian, and A. Xu. 2022. FGF21-Sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity. Circulation 146:1537\u20131557.","journal-title":"Circulation"},{"key":"2309_CR21","first-page":"892","volume":"56","author":"Y Heng","year":"2024","unstructured":"Heng, Y., W. Wei, L. Cheng, F. Wu, H. Dong, J. Li, J. Fu, B. Yang, X. Liang, C. Liu, H. Li, H. Liu, and P. Zhang. 2024. FGF21 overexpression alleviates VSMC senescence in diabetic mice by modulating the SYK-NLRP3 inflammasome-PPARgamma-catalase pathway. Acta Biochimica et Biophysica Sinica (Shanghai) 56:892\u2013904.","journal-title":"Acta Biochimica et Biophysica Sinica (Shanghai)"},{"issue":"5","key":"2309_CR22","doi-asserted-by":"publisher","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","volume":"4","author":"S Osataphan","year":"2019","unstructured":"Osataphan, S., C. Macchi, G. Singhal, J. Chimene-Weiss, V. Sales, C. Kozuka, J. M. Dreyfuss, H. Pan, Y. Tangcharoenpaisan, J. Morningstar, R. Gerszten, and M. E. Patti. 2019. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight 4 (5): e123130.","journal-title":"JCI Insight"},{"key":"2309_CR23","doi-asserted-by":"publisher","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","volume":"13","author":"M Packer","year":"2020","unstructured":"Packer, M. 2020. Cardioprotective effects of Sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors. Circulation Heart Failure 13:e007197.","journal-title":"Circulation Heart Failure"},{"key":"2309_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.cmet.2018.04.002","volume":"27","author":"X Pan","year":"2018","unstructured":"Pan, X., Y. Shao, F. Wu, Y. Wang, R. Xiong, J. Zheng, H. Tian, B. Wang, Y. Wang, Y. Zhang, Z. Han, A. Qu, H. Xu, A. Lu, T. Yang, X. Li, A. Xu, J. Du, and Z. Lin. 2018. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2\/Angiotensin-(1\u20137) axis in mice. Cell Metabolism 27:1323-1337 e5.","journal-title":"Cell Metabolism"},{"key":"2309_CR25","doi-asserted-by":"publisher","first-page":"172537","DOI":"10.1016\/j.ejphar.2019.172537","volume":"860","author":"S A Norgaard","year":"2019","unstructured":"Norgaard, S. A., F. Briand, F. W. Sand, E. D. Galsgaard, H. Sondergaard, D. B. Sorensen, and T. Sulpice. 2019. Nephropathy in diabetic db\/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin. European Journal of Pharmacology 860:172537.","journal-title":"European Journal of Pharmacology"},{"key":"2309_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.115.020754","volume":"134","author":"L Wang","year":"2016","unstructured":"Wang, L., X. C. Zhao, W. Cui, Y. Q. Ma, H. L. Ren, X. Zhou, J. Fassett, Y. Z. Yang, Y. Chen, Y.L. Xia, J. Du, and H. H. Li. 2016. Genetic and pharmacologic inhibition of the chemokine receptor CXCR2 prevents experimental hypertension and vascular dysfunction. Circulation 134:1353\u20131368.","journal-title":"Circulation"},{"key":"2309_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.freeradbiomed.2016.07.013","volume":"97","author":"E Di Marco","year":"2016","unstructured":"Di Marco, E., S. P. Gray, K. Kennedy, C. Szyndralewiez, A. N. Lyle, B. Lassegue, K. K. Griendling, M. E. Cooper, H. Schmidt, and K. A. M. Jandeleit-Dahm. 2016. NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis. Free Radical Biology & Medicine 97:556\u2013567.","journal-title":"Free Radical Biology & Medicine"},{"key":"2309_CR28","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1096\/fj.201902692R","volume":"34","author":"H Che","year":"2020","unstructured":"Che, H., Y. Wang, H. Li, Y. Li, A. Sahil, J. Lv, Y. Liu, Z. Yang, R. Dong, H. Xue, and L. Wang. 2020. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1\/miR-141-mediated NLRP3 inflammasome and TGF-beta1\/Smads signaling in diabetic cardiomyopathy. The FASEB Journal 34:5282\u20135298.","journal-title":"The FASEB Journal"},{"key":"2309_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2022.04.007","volume":"356","author":"C Zhuang","year":"2022","unstructured":"Zhuang, C., Z. Guo, J. Zhu, W. Wang, R. Sun, M. Qi, Q. Wang, X. Fan, R. Ma, and J. Yu. 2022. PTEN inhibitor attenuates cardiac fibrosis by regulating the M2 macrophage phenotype via the PI3K\/AKT\/TGF-beta\/Smad 2\/3 signaling pathway. International Journal of Cardiology 356:88\u201396.","journal-title":"International Journal of Cardiology"},{"key":"2309_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/jpp\/rgad043","volume":"75","author":"V K Vishwakarma","year":"2023","unstructured":"Vishwakarma, V. K., S. Shah, T. Kaur, A. P. Singh, S. K. Arava, N. Kumar, R. K. Yadav, S. Yadav, T. Arora, and H. N. Yadav. 2023. Effect of vinpocetine alone and in combination with enalapril in experimental model of diabetic cardiomyopathy in rats: Possible involvement of PDE-1\/TGF-beta\/ Smad 2\/3 signalling pathways. Journal of Pharmacy and Pharmacology 75:1198\u20131211.","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"2309_CR31","doi-asserted-by":"publisher","first-page":"153338","DOI":"10.1016\/j.tox.2022.153338","volume":"480","author":"P Lin","year":"2022","unstructured":"Lin, P., X. Tong, F. Xue, C. Qianru, T. Xinyu, L. Zhe, B. Zhikun, and L. Shu. 2022. Polystyrene nanoplastics exacerbate lipopolysaccharide-induced myocardial fibrosis and autophagy in mice via ROS\/TGF-beta1\/Smad. Toxicology 480:153338.","journal-title":"Toxicology"},{"key":"2309_CR32","doi-asserted-by":"publisher","first-page":"174354","DOI":"10.1016\/j.ejphar.2021.174354","volume":"908","author":"J Sun","year":"2021","unstructured":"Sun, J., J. Zhu, L. Chen, B. Duan, R. Wang, M. Zhang, J. Xu, W. Liu, Y. Xu, F. Feng, and W. Qu. 2021. Forsythiaside B inhibits myocardial fibrosis via down regulating TGF-beta1\/Smad signaling pathway. European Journal of Pharmacology 908:174354.","journal-title":"European Journal of Pharmacology"},{"key":"2309_CR33","first-page":"831","volume":"4","author":"O Iborra-Egea","year":"2019","unstructured":"Iborra-Egea, O., E. Santiago-Vacas, S. R. Yurista, J. Lupon, M. Packer, S. Heymans, F. Zannad, J. Butler, D. Pascual-Figal, A. Lax, J. Nunez, R. A. de Boer, and A. Bayes-Genis. 2019. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC: Basic to Translational Science 4:831\u2013840.","journal-title":"JACC: Basic to Translational Science"},{"key":"2309_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang, S., S. Verma, A. F. Hassanabad, G. Teng, D. D. Belke, J. A. Dundas, D. G. Guzzardi, D. A. Svystonyuk, S. S. Pattar, D. S. J. Park, J. D. Turnbull, H. J. Duff, L. A. Tibbles, R. H. Cunnington, J. R. B. Dyck, and P. W. M. Fedak. 2020. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: Novel translational clues to explain EMPA-REG OUTCOME results. Canadian Journal of Cardiology 36:543\u2013553.","journal-title":"Canadian Journal of Cardiology"},{"key":"2309_CR35","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/dom.13299","volume":"20","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod, M., K. I. Birkeland, M. A. Cavender, A. Z. Fu, J. P. Wilding, K. Khunti, R. W. Holl, A. Norhammar, M. E. Jorgensen, E. T. Wittbrodt, M. Thuresson, J. Bodegard, N. Hammar, P. Fenici, Investigators, C.-R. & Study, G. 2018. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Diabetes, Obesity and Metabolism 20:1983\u20131987.","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"2309_CR36","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma, S., C. D. Mazer, A. T. Yan, T. Mason, V. Garg, H. Teoh, F. Zuo, A. Quan, M. E. Farkouh, D. H. Fitchett, S. G. Goodman, R. M. Goldenberg, M. Al-Omran, R. E. Gilbert, D. L. Bhatt, L. A. Leiter, P. Juni, B. Zinman, and K. A. Connelly. 2019. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 140:1693\u20131702.","journal-title":"Circulation"},{"key":"2309_CR37","doi-asserted-by":"crossref","unstructured":"Sarafidis, P. A., and Tsapas, A. 2016. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 374 (11): 1092.","DOI":"10.1056\/NEJMc1600827"},{"key":"2309_CR38","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","volume":"35","author":"D C Wheeler","year":"2020","unstructured":"Wheeler, D. C., B. V. Stefansson, M. Batiushin, O. Bilchenko, D. Z. I. Cherney, G. M. Chertow, W. Douthat, J. P. Dwyer, E. Escudero, R. Pecoits-Filho, H. Furuland, J. L. Gorriz, T. Greene, H. Haller, F. F. Hou, S. W. Kang, R. Isidto, D. Khullar, P. B. Mark, J. J. V. McMurray, N. Kashihara, M. Nowicki, F. Persson, R. Correa-Rotter, P. Rossing, R. D. Toto, K. Umanath, P. Van Bui, I. Wittmann, M. Lindberg, C. D. Sjostrom, A. M. Langkilde, and H. J. L. Heerspink. 2020. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics. Nephrology, Dialysis, Transplantation 35:1700\u20131711.","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"2309_CR39","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari, A., F. Cappelli, C. Nitsche, D. Tomasoni, G. Sinigiani, S. Longhi, L. Bordignon, A. Masri, M. Serenelli, M. Urey, B. Musumeci, A. Cipriani, M. Canepa, R. Badr-Eslam, C. Kronberger, C. Chimenti, M. Zampieri, V. Allegro, Y. Razvi, R. Patel, A. Ioannou, M. U. Rauf, A. Petrie, C. Whelan, M. Emdin, M. Metra, M. Merlo, G. Sinagra, P. N. Hawkins, S. D. Solomon, J. D. Gillmore, and M. Fontana. 2024. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. Journal of the American College of Cardiology. 83:2411\u20132422.","journal-title":"Journal of the American College of Cardiology."},{"key":"2309_CR40","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","volume":"325","author":"X Chen","year":"2023","unstructured":"Chen, X., C. F. Hocher, L. Shen, B. K. Kramer, and B. Hocher. 2023. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: From bedside to bench. American Journal of Physiology. Cell Physiology 325:C661\u2013C681.","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"2309_CR41","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"Y M Gao","year":"2022","unstructured":"Gao, Y. M., S. T. Feng, Y. Wen, T. T. Tang, B. Wang, and B. C. Liu. 2022. Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming. eBioMedicine 83:104215.","journal-title":"eBioMedicine"},{"key":"2309_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer, M. 2022. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146:1383\u20131405.","journal-title":"Circulation"},{"key":"2309_CR43","doi-asserted-by":"publisher","first-page":"176712","DOI":"10.1016\/j.ejphar.2024.176712","volume":"978","author":"G Zhan","year":"2024","unstructured":"Zhan, G., X. Wang, X. Wang, J. Li, Y. Tang, H. Bi, X. Yang, and Y. Xia. 2024. Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling. European Journal of Pharmacology 978:176712.","journal-title":"European Journal of Pharmacology"},{"key":"2309_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","volume":"78","author":"F M Fisher","year":"2016","unstructured":"Fisher, F. M., and E. Maratos-Flier. 2016. Understanding the physiology of FGF21. Annual Review of Physiology 78:223\u2013241.","journal-title":"Annual Review of Physiology"},{"key":"2309_CR45","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1007\/s11033-021-06707-0","volume":"48","author":"F Meng","year":"2021","unstructured":"Meng, F., M. H. Khoso, K. Kang, Q. He, Y. Cao, X. Jiang, W. Xiao, and D. Li. 2021. FGF21 ameliorates hepatic fibrosis by multiple mechanisms. Molecular Biology Reports 48:7153\u20137163.","journal-title":"Molecular Biology Reports"},{"key":"2309_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/a-1778-4159","volume":"54","author":"E Szczepanska","year":"2022","unstructured":"Szczepanska, E., and M. Gietka-Czernel. 2022. FGF21: A novel regulator of glucose and lipid metabolism and whole-body energy balance. Hormone and Metabolic Research 54:203\u2013211.","journal-title":"Hormone and Metabolic Research"},{"key":"2309_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/ijbs.73936","volume":"19","author":"H Tan","year":"2023","unstructured":"Tan, H., T. Yue, Z. Chen, W. Wu, S. Xu, and J. Weng. 2023. Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine. International Journal of Biological Sciences 19:66\u201388.","journal-title":"International Journal of Biological Sciences"},{"key":"2309_CR48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/jcmm.17154","volume":"26","author":"M Wang","year":"2022","unstructured":"Wang, M., L. Su, J. Sun, L. Cai, X. Li, X. Zhu, L. Song, J. Li, S. Tong, Q. He, M. Cai, L. Yang, Y. Chen, L. Wang, and X. Huang. 2022. FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARgamma. Journal of Cellular and Molecular Medicine 26:1034\u20131049.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"2309_CR49","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00380-014-0557-9","volume":"30","author":"X Wu","year":"2015","unstructured":"Wu, X., Y. F. Qi, J. R. Chang, W. W. Lu, J. S. Zhang, S. P. Wang, S. J. Cheng, M. Zhang, Q. Fan, Y. Lv, H. Zhu, M. K. Xin, Y. Lv, and J. H. Liu. 2015. Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-\/-) mice. Heart and Vessels 30:657\u2013668.","journal-title":"Heart and Vessels"},{"key":"2309_CR50","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/hy09t1.096249","volume":"38","author":"H D Intengan","year":"2001","unstructured":"Intengan, H. D., and E. L. Schiffrin. 2001. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension 38:581\u2013587.","journal-title":"Hypertension"},{"key":"2309_CR51","doi-asserted-by":"publisher","first-page":"101527","DOI":"10.1016\/j.redox.2020.101527","volume":"32","author":"G Behnammanesh","year":"2020","unstructured":"Behnammanesh, G., G. L. Durante, Y. P. Khanna, K. J. Peyton, and W. Durante. 2020. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. Redox Biology 32:101527.","journal-title":"Redox Biology"},{"key":"2309_CR52","doi-asserted-by":"publisher","first-page":"109182","DOI":"10.1016\/j.jnutbio.2022.109182","volume":"111","author":"J Pan","year":"2023","unstructured":"Pan, J., R. Wang, Y. Pei, D. Wang, N. Wu, Y. Ji, Q. Tang, L. Liu, K. Cheng, Q. Liu, J. Sun, M. Gong, X. Zheng, J. Li, C. Zhang, and Y. Yuan. 2023. Sulforaphane alleviated vascular remodeling in hypoxic pulmonary hypertension via inhibiting inflammation and oxidative stress. Journal of Nutritional Biochemistry 111:109182.","journal-title":"Journal of Nutritional Biochemistry"},{"key":"2309_CR53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2174\/1570161119999201103191242","volume":"19","author":"R Tavakoli","year":"2021","unstructured":"Tavakoli, R., J. Tabeshpour, J. Asili, A. Shakeri, and A. Sahebkar. 2021. Cardioprotective effects of natural products via the Nrf2 signaling pathway. Current Vascular Pharmacology 19:525\u2013541.","journal-title":"Current Vascular Pharmacology"},{"key":"2309_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.intimp.2016.05.026","volume":"38","author":"Y Yu","year":"2016","unstructured":"Yu, Y., J. He, S. Li, L. Song, X. Guo, W. Yao, D. Zou, X. Gao, Y. Liu, F. Bai, G. Ren, and D. Li. 2016. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-kappaB signaling pathway. International Immunopharmacology 38:144\u2013152.","journal-title":"International Immunopharmacology"},{"key":"2309_CR55","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00441-016-2445-3","volume":"365","author":"K Richter","year":"2016","unstructured":"Richter, K., and T. Kietzmann. 2016. Reactive oxygen species and fibrosis: Further evidence of a significant liaison. Cell and Tissue Research 365:591\u2013605.","journal-title":"Cell and Tissue Research"},{"key":"2309_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00726-021-03005-8","volume":"53","author":"J Li","year":"2021","unstructured":"Li, J., H. Ding, Y. Li, H. Zhou, W. Wang, Y. Mei, and R. Zhang. 2021. Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats. Amino Acids 53:1079\u20131089.","journal-title":"Amino Acids"},{"key":"2309_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40168-024-01872-3","volume":"12","author":"H Zheng","year":"2024","unstructured":"Zheng, H., X. Zhang, C. Li, D. Wang, Y. Shen, J. Lu, L. Zhao, X. Li, and H. Gao. 2024. BCAA mediated microbiota-liver-heart crosstalk regulates diabetic cardiomyopathy via FGF21. Microbiome 12:157.","journal-title":"Microbiome"},{"key":"2309_CR58","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","volume":"16","author":"K Zhang","year":"2025","unstructured":"Zhang, K., J. Gan, B. Wang, W. Lei, D. Zhen, J. Yang, N. Wang, C. Wen, X. Gao, X. Li, A. Xu, X. Liu, Y. Li, F. Wu, and Z. Lin. 2025. FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice. Nature Communications 16:1661.","journal-title":"Nature Communications"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-025-02309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-025-02309-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-025-02309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T01:02:58Z","timestamp":1766451778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-025-02309-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1007\/s10753-025-02309-1","relation":{},"ISSN":["1573-2576"],"issn-type":[{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal protocol of this study was approved by the Ethics Committee of Anhui Medical University (Anhui Medical Ethics Approval No. LLSC20190530), and all experimental methods and procedures were carried out in accordance with the National Institutes of Health guidelines (Publication No. 8523) to comply with all relevant ethical regulations for animal testing and research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}